These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32947564)

  • 21. Spatial Systems Lipidomics Reveals Nonalcoholic Fatty Liver Disease Heterogeneity.
    Ščupáková K; Soons Z; Ertaylan G; Pierzchalski KA; Eijkel GB; Ellis SR; Greve JW; Driessen A; Verheij J; De Kok TM; Olde Damink SWM; Rensen SS; Heeren RMA
    Anal Chem; 2018 Apr; 90(8):5130-5138. PubMed ID: 29570976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.
    Peng KY; Watt MJ; Rensen S; Greve JW; Huynh K; Jayawardana KS; Meikle PJ; Meex RCR
    J Lipid Res; 2018 Oct; 59(10):1977-1986. PubMed ID: 30042157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis.
    Goda K; Saito K; Muta K; Kobayashi A; Saito Y; Sugai S
    J Toxicol Sci; 2018; 43(6):395-405. PubMed ID: 29877216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma lipidomics reveals potential lipid markers of major depressive disorder.
    Liu X; Li J; Zheng P; Zhao X; Zhou C; Hu C; Hou X; Wang H; Xie P; Xu G
    Anal Bioanal Chem; 2016 Sep; 408(23):6497-507. PubMed ID: 27457104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic Lipidomics Analysis Reveals the Ameliorative Effects of Highland Barley β-Glucan on Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice.
    Liu H; Chen T; Xie X; Wang X; Luo Y; Xu N; Sa Z; Zhang M; Chen Z; Hu X; Li J
    J Agric Food Chem; 2021 Aug; 69(32):9287-9298. PubMed ID: 34347479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease.
    Deng KQ; Huang X; Lei F; Zhang XJ; Zhang P; She ZG; Cai J; Ji YX; Li H
    Am J Physiol Cell Physiol; 2022 Aug; 323(2):C630-C639. PubMed ID: 35759443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Xu QY; Li H; Cao HX; Pan Q; Fan JG
    Biomed Res Int; 2020; 2020():8869674. PubMed ID: 33294458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.
    Notarnicola M; Osella AR; Caruso MG; Pesole PL; Lippolis A; Tutino V; Bonfiglio C; De Nunzio V; Scavo MP; Mirizzi A; Franco I; Lippolis T; D'Alessandro R; Refolo MG; Messa C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.
    Masoodi M; Gastaldelli A; Hyötyläinen T; Arretxe E; Alonso C; Gaggini M; Brosnan J; Anstee QM; Millet O; Ortiz P; Mato JM; Dufour JF; Orešič M
    Nat Rev Gastroenterol Hepatol; 2021 Dec; 18(12):835-856. PubMed ID: 34508238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
    Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
    J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responses of the Serum Lipid Profile to Exercise and Diet Interventions in Nonalcoholic Fatty Liver Disease.
    Qi Z; LE S; Cheng R; DU X; Zhao C; Zhang Z; Zhang X; Feng L; Schumann M; Mao L; Cheng S
    Med Sci Sports Exerc; 2024 Jun; 56(6):1036-1045. PubMed ID: 38247038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Hepatic Tissue Copper in Pediatric Nonalcoholic Fatty Liver Disease.
    Mendoza M; Caltharp S; Song M; Collin L; Konomi JV; McClain CJ; Vos MB
    J Pediatr Gastroenterol Nutr; 2017 Jul; 65(1):89-92. PubMed ID: 28644356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats.
    Deng Y; Pan M; Nie H; Zheng C; Tang K; Zhang Y; Yang Q
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31683679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis.
    Qian M; Hu H; Yao Y; Zhao D; Wang S; Pan C; Duan X; Gao Y; Liu J; Zhang Y; Yang S; Qi LW; Wang L
    Liver Int; 2020 Mar; 40(3):622-637. PubMed ID: 31782595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD.
    Weber M; Mera P; Casas J; Salvador J; Rodríguez A; Alonso S; Sebastián D; Soler-Vázquez MC; Montironi C; Recalde S; Fucho R; Calderón-Domínguez M; Mir JF; Bartrons R; Escola-Gil JC; Sánchez-Infantes D; Zorzano A; Llorente-Cortes V; Casals N; Valentí V; Frühbeck G; Herrero L; Serra D
    FASEB J; 2020 Sep; 34(9):11816-11837. PubMed ID: 32666604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipidomics in non-alcoholic fatty liver disease.
    Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
    World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Osteocalcin Levels in Children With Nonalcoholic Fatty Liver Disease.
    Amin S; El Amrousy D; Elrifaey S; Gamal R; Hodeib H
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):117-121. PubMed ID: 28991837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.